Browse medicines, page 6 of 10
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Showing 301–360 of 546 records
Ropeginterferon Alfa-2b (Besremi)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Polycythemia vera
Sea Scallop (Scallops)
Protein medicineLaboratory or animal-stage researchExpanded recordSerratiopeptidase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordSomatrogon (Ngenla)
Protein medicineLaboratory or animal-stage researchExpanded recordSouthern Flounder (Flounder)
Protein medicineLaboratory or animal-stage researchExpanded recordSpesolimab-Sbzo (Spevigo)
Protein medicineApproved in the United States (FDA)Expanded recordStreptococcus Pneumoniae Type 15b Capsular Polysaccharide Antigen (Pneumovax 23)
Protein medicineLaboratory or animal-stage researchExpanded recordStreptococcus Pneumoniae Type 7f Capsular Polysaccharide Diphtheria Crm197 Protein Conjugate Antigen (Vaxneuvance / Capvaxive / Prevnar 13 / Prevnar 20)
Protein medicineLaboratory or animal-stage researchExpanded recordSucrase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordSutimlimab-Jome (Enjaymo)
Protein medicineApproved in the United States (FDA)Expanded recordTannase
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordTechnetium Tc-99m Tilmanocept (Lymphoseek Kit)
Protein medicineApproved in the United States (FDA)Expanded recordTenecteplase (Tnkase)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Acute ischemic stroke
Tocilizumab-Bavi (Tofidence)
Protein medicineApproved in the United States (FDA)Expanded recordAlbumin Chromated Cr-51 Serum (Chromalbin)
Protein medicineApproved in the United States (FDA)Expanded recordAnacaulase-Bcdb (Nexobrid)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Eschar removal
Bevacizumab-Nwgd (Jobevne)
Protein medicineApproved in the United States (FDA)Expanded recordBevacizumab-Tnjn (Avzivi)
Protein medicineApproved in the United States (FDA)Expanded recordBimekizumab-Bkzx (Bimzelx)
Protein medicineApproved in the United States (FDA)Expanded recordBotulinum Toxin Type B (Myobloc)
Protein medicineApproved in the United States (FDA)Expanded recordBurosumab-Twza (Crysvita)
Protein medicineApproved in the United States (FDA)Expanded recordCollagenase Clostridium Histolyticum (Xiaflex / Collagenase Santyl)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Dupuytren’s contracture with a palpable cord
Corticorelin Ovine Triflutate (Acthrel)
Protein medicineApproved in the United States (FDA)Expanded recordCosibelimab-Ipdl (Unloxcyt)
Protein medicineApproved in the United States (FDA)Expanded recordDatopotamab Deruxtecan-Dlnk (Datroway)
Protein medicineApproved in the United States (FDA)Expanded recordDenosumab-Bmwo (Osenvelt / Stoboclo)
Protein medicineApproved in the United States (FDA)Expanded recordEculizumab-Aagh (Epysqli)
Protein medicineApproved in the United States (FDA)Expanded recordEfbemalenograstim Alfa-Vuxw (Ryzneuta)
Protein medicineApproved in the United States (FDA)Expanded recordEflapegrastim (Rolvedon)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.
Elosulfase alfa (Vimizim)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Mucopolysaccharidosis type IVA (MPS IVA
Emapalumab-Lzsg (Gamifant)
Protein medicineApproved in the United States (FDA)Expanded recordEtanercept-Szzs (Erelzi)
Protein medicineApproved in the United States (FDA)Expanded recordEtanercept-Ykro (Eticovo)
Protein medicineApproved in the United States (FDA)Expanded recordEvinacumab-Dgnb (Evkeeza)
Protein medicineApproved in the United States (FDA)Expanded recordFilgrastim-Sndz (Zarxio)
Protein medicineApproved in the United States (FDA)Expanded recordInebilizumab-Cdon (Uplizna)
Protein medicineApproved in the United States (FDA)Expanded recordInfliximab-Dyyb (Zymfentra / Inflectra)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
ZYMFENTRA is a tumor necrosis factor (TNF) blocker indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously. ( 1 ) moderately to severely active Crohn’s disease following with an infliximab products administered intraneously. ( 1 ) ZYMFENTRA is indicated in adults for maintenance treatment of: moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously.
Influenza B Virus B/Tokyo/Eis13-175/2025 Antigen (Fluzone Trivalent Northern Hemisphere / Fluzone High Dose Northern Hemisphere / Fluad / Flulaval 2026/2027)
Protein medicineLaboratory or animal-stage researchExpanded recordInsulin Glargine-Aldy (Langlara)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Glulisine (Apidra)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
Glycemic control
Insulin Icodec (Awiqli)
Protein medicineApproved in the United States (FDA)Expanded recordInsulin Pork (Metabolism Manager / Ha2cg Evolution / Glucoreg / Fcs Cp / Professional Weight Support / Hgh)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
HOMEOPATHIC INDICATIONS: For temporary relief of symptoms related to high blood sugar including dry mouth, thirst, night sweats, sugar and carb cravings.** **These statements are based upon traditional homeopathic principles. They have not been reviewed by the Food and Drug Administration.
Interferon Alfa-2b (Intron A)
Protein medicineApproved in the United States (FDA)Expanded recordInterferon Beta-1a (Rebif / Avonex / Rebif Rebidose)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
REBIF is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Rebif is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Interferon Beta-1b (Betaseron)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BETASERON is an interferon beta indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )
Interferon Gamma-1b (Actimmune / Guna-Inf gamma)
Protein medicineApproved in the United States (FDA)Expanded recordUse listed on the medicine record
Reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease
Isatuximab-Irfc (Sarclisa / Sarclisa Escena)
Protein medicineApproved in the United States (FDA)Expanded recordLebrikizumab-Lbkz (Ebglyss)
Protein medicineApproved in the United States (FDA)Expanded recordLerodalcibep (Lerochol)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Low-density lipoprotein cholesterol
Lerodalcibep-Liga (Lerochol)
Protein medicineApproved in the United States (FDA)Expanded recordLinvoseltamab-Gcpt (Lynozyfic)
Protein medicineApproved in the United States (FDA)Expanded recordMarstacimab-Hncq (Hympavzi)
Protein medicineApproved in the United States (FDA)Expanded recordMirvetuximab Soravtansine (Elahere)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )].
Moxetumomab Pasudotox-Tdfk (Lumoxiti)
Protein medicineApproved in the United States (FDA)Expanded recordNeisseria Meningitidis Group C Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen (Menquadfi)
Protein medicineLaboratory or animal-stage researchExpanded recordNeisseria Meningitidis Group W-135 Capsular Polysaccharide Tetanus Toxoid Conjugate Antigen (Menquadfi)
Protein medicineLaboratory or animal-stage researchExpanded recordOcrelizumab and Hyaluronidase-Ocsq (Ocrevus Zunovo)
Protein medicineApproved in the United States (FDA)Expanded recordOlipudase alfa (Xenpozyme)
Protein medicineLaboratory or animal-stage researchExpanded recordUse listed on the medicine record
Treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency
Omalizumab-Igec (Omlyclo)
Protein medicineApproved in the United States (FDA)Expanded recordOrthoclase (Lepidolite 8130)
Protein medicineDietary supplement; not FDA-approved as a medicineExpanded recordUse listed on the medicine record
INDICATIONS Temporarily relieves hopelessness, worry, impatience, low self-esteem, or mental/emotional imbalance.*